AIM
ADVM

Acrospire Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

Acrospire Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-240
Closed -$6K – 2136
2017
Q1 		$6K Sell
240
-282
-54% -$8.02K 0.01% 1958
2016
Q4 		$15K Buy
+522
New +$17.1K 0.01% 1849

Other funds holding ADVM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acrospire Investment Management's ADVM Position: Q2 2017 in Review

Acrospire Investment Management sold out of Adverum Biotechnologies (ADVM) in Q2 2017, closing a stake of 240 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in ADVM in Q4 2016 and held it in 2 quarters. The position peaked at $15K in Q4 2016. 63 funds tracked by Wall St. Rank hold ADVM as of Q2 2017.

  • Acrospire Investment Management reported no remaining Adverum Biotechnologies position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 240 Adverum Biotechnologies shares in Q2 2017, an estimated $6K.
  • Acrospire Investment Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Adverum Biotechnologies position peaked at $15K in Q4 2016.
  • 63 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.